- Comparisons of clinicopathological characteristics and survival between the non-pathological complete response and pathological complete response groups of elderly women with triple-negative invasive ductal breast cancer after neoadjuvant chemotherapy.
| Characteristics | Non-pathological complete response (n=285) | Pathological complete response (n=97) | P-values |
|---|---|---|---|
| Age, years | |||
| 70-74 | 153 (53.7) | 55 (56.7) | 0.585 |
| 75-79 | 90 (31.6) | 28 (28.9) | |
| 80-84 | 25 (8.8) | 11 (11.3) | |
| ≥85 | 17 (6.0) | 3 (3.0) | |
| Race | |||
| White | 197 (69.1) | 73 (75.3) | 0.751 |
| Black | 52 (18.2) | 14 (14.4) | |
| Asian or Pacific Islander | 30 (10.5) | 9 (9.3) | |
| American Indian/Alaska Native | 6 (2.1) | 1 (1.0) | |
| SEER summary stage | |||
| Local involvement | 77 (27.0) | 45 (46.4) | 0.003 |
| Direct spread | 17 (6.0) | 5 (5.2) | |
| Regional lymph node involvement | 103 (36.1) | 32 (33.0) | |
| Direct spread and regional lymph node involvement | 58 (20.4) | 12 (12.4) | |
| Distant metastasis | 30 (10.5) | 3 (3.1) | |
| TNM | |||
| I | 26 (9.1) | 15 (15.5) | <0.001 |
| II | 114 (40.0) | 57 (58.8) | |
| III | 118 (41.4) | 23 (23.7) | |
| IV | 27 (9.4) | 2 (2.1) | |
| Tumor location | |||
| Center | 16 (5.6) | 4 (4.1) | 0.481 |
| Axillary tail | 1 (0.4) | 0 (0.0) | |
| Lower outer quadrant | 25 (8.8) | 6 (6.2) | |
| Upper outer quadrant | 102 (35.8) | 33 (34.0) | |
| Lower inner quadrant | 13 (4.6) | 11 (11.3) | |
| Upper inner quadrant | 26 (9.1) | 8 (8.2) | |
| Overlapping region | 61 (21.4) | 23 (23.7) | |
| Unknown region | 41 (14.4) | 12 (12.4) | |
| Surgery, yes | 277 (97.2) | 97 (100) | 0.209 |
| Disease-specific survival, yes | 158 (55.4) | 86 (88.7) | <0.001 |
| Overall survival, yes | 249 (87.4) | 86 (88.7) | 0.876 |
Values are presented as numbers and percentages (%). Statistical tests were either Chi-square test (all categories with % ≥5) or Fisher-Freeman-Halton test (for multiple categorical variables that did not satisfy Chi-square test conditions). SEER: surveillance, epidemiology, and end results, TNM: tumor, node, and metastasis